Navigation Links
Ardea Biosciences Announces $40 Million Private Placement
Date:12/20/2007

CARLSBAD, Calif., Dec. 20 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a company focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases, today announced that it has entered into a securities purchase agreement with certain institutional investors to raise approximately $40 million from the private placement of approximately 3.0 million newly issued shares of its common stock at a price of $13.25 per share. Subject to the satisfaction of customary closing conditions, the financing is expected to close on or about December 21, 2007.

Piper Jaffray & Co. acted as lead placement agent for this offering, with Cowen and Company and Oppenheimer & Co. Inc. acting as co-placement agents.

The shares of Ardea's common stock to be sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from the registration requirements. The shares were offered and will be sold only to a limited number of accredited investors. Ardea has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issued in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy Ardea's common stock.

About Ardea Biosciences, Inc.

Ardea Biosciences is focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases. The Company plans to have active development
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
7. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
8. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... , , SEATTLE, Nov. 20 /PRNewswire-FirstCa... announced that the U.S. Food and Drug Administrat...e Company,s amended Biologics License Application ...ete response. The FDA has assigned a Prescription... which time it will respond to Dendreon,s amended ...
(Date:11/20/2009)... , METTLER TOLEDO recentl...nt a free webinar, “The Role of Process Anal...en Engineering” on December 1, 2009. , ...uring the The Role of Process Analytical Technolo...Webinar on December 1, Process Analytical Technol...
(Date:11/19/2009)... , , ,, BETHESDA, Md., Nov. 19 /P...aq: SPEX ), an innovator in biotechnology for dia...ulatory consulting services to food, supplement, b...ed today it closed the previously reported $6.3 mi... investors of 2,760,870 shares of its common stock...
(Date:11/19/2009)... , , MONTREAL, Nov. 19 /PRNewswire/ - Aege... the first patient in a randomized Phase 2B study ...id-stage development for multiple oncology indicat...domized Phase 2 Study of the X-Linked Inhibitor of...ination with High-dose Cytarabine and Idarubicin i...
Breaking Biology Technology:Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
...notech ,09 and the TechConnect Summit are the Larg..., Bio and Clean Tech Solutions From Development to... TechConnect World, in association with the Nano ...lean Technology and Sustainable Industries Organiz... presentations will be featured in the Clean Techn...
... Biomerix Corporation announced today that it has...510(k) clearance to market REVIVE(TM). Constructed...s a tissue scaffold facilitating rapid tissue ingr...ue repair procedures, including the repair of ingu...res per year, inguinal hernia repair is one of the...
...CUXHAVEN, Germany, February 26 ,EUCODIS Bioscience...ndustry,and Lohmann Animal Health (LAH), a company...ition and animal health, today announced the achie...ollaboration agreement relating to the,optimizatio...nce has completed the development of the prototype...
Other Biology Technology:TechConnect World Publishes Conference Agenda Featuring More than 2,700 Presentations Addressing Nano, Bio and Clean Technologies 2TechConnect World Publishes Conference Agenda Featuring More than 2,700 Presentations Addressing Nano, Bio and Clean Technologies 3TechConnect World Publishes Conference Agenda Featuring More than 2,700 Presentations Addressing Nano, Bio and Clean Technologies 4TechConnect World Publishes Conference Agenda Featuring More than 2,700 Presentations Addressing Nano, Bio and Clean Technologies 5Biomerix Corporation Announces FDA Clearance and Market Launch of REVIVE(TM) for Use in Soft Tissue Repair Procedures 2EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone 2EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone 3
(Date:11/20/2009)...D), a respiratory disease commonly known as chroni...ause of death worldwide. 600 million people live ...ny real treatment or cure, Grace Parraga of Robart...Ontario in London, Canada, is using various imagin... , Parraga is a scientist in the Imaging Res...
(Date:11/19/2009)...end of the last ice age, North America,s vast asse...atures as mammoths, mastodons, camels, horses, gro...ous slide to extinction. , And when their popula...large animals equaled or surpassed Africa,s wildli...novel ecosystem emerged as broadleaved trees once ...
(Date:11/19/2009)...: The offspring of two inbred strains tend to be s...he gene-level variability that leads to this pheno...oost our ability to custom-tailor crops for specif...consumption or high glucose content for biomass fu...uence of the common corn strain B73, University of...
Breaking Biology News(10 mins):Gaining a better picture of lung disease 2After mastodons and mammoths, a transformed landscape 2After mastodons and mammoths, a transformed landscape 3U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2Reportlinker Adds Synthetic Biology 3A Emerging Global Markets Report 13841 1Reportlinker Adds Synthetic Biology 3A Emerging Global Markets Report 13841 2Reportlinker Adds Synthetic Biology 3A Emerging Global Markets Report 13841 3Reportlinker Adds Synthetic Biology 3A Emerging Global Markets Report 13841 4Reportlinker Adds Synthetic Biology 3A Emerging Global Markets Report 13841 5Reportlinker Adds Synthetic Biology 3A Emerging Global Markets Report 13841 6Reportlinker Adds Synthetic Biology 3A Emerging Global Markets Report 13841 7Reportlinker Adds Synthetic Biology 3A Emerging Global Markets Report 13841 8Reportlinker Adds Synthetic Biology 3A Emerging Global Markets Report 13841 9Reportlinker Adds Synthetic Biology 3A Emerging Global Markets Report 13841 10Reportlinker Adds Synthetic Biology 3A Emerging Global Markets Report 13841 11Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 1Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 2Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 3Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 4Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 5Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 6Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 7Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 8Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 9Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 10Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 11Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 12Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 13Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 14Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 15Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 16Reportlinker Adds the Dental Market 3A Techniques Equipment and Materials Report 56181 17Reportlinker Adds Antiseptics and Disinfectants Report 56178 1Reportlinker Adds Antiseptics and Disinfectants Report 56178 2Reportlinker Adds Antiseptics and Disinfectants Report 56178 3Reportlinker Adds Antiseptics and Disinfectants Report 56178 4Reportlinker Adds Antiseptics and Disinfectants Report 56178 5Reportlinker Adds Antiseptics and Disinfectants Report 56178 6Reportlinker Adds Antiseptics and Disinfectants Report 56178 7Reportlinker Adds Antiseptics and Disinfectants Report 56178 8Reportlinker Adds Antiseptics and Disinfectants Report 56178 9Reportlinker Adds Antiseptics and Disinfectants Report 56178 10Reportlinker Adds Antiseptics and Disinfectants Report 56178 11Reportlinker Adds Antiseptics and Disinfectants Report 56178 12
...May 27, 2009) The Foundation for Digestive Health...troenterological Association (AGA) Foundation Rese...e outstanding young gastroenterologists who promis...rointestinal research. , "With the current econo...l scientists, especially those young scientists ju...
...rdsong resembles the learning of speech in humans....nd the ability to produce sound. Social isolation ...ans and in birds. When children grow up without co...rudimentary form of human language. , A similar s...oved from their parents and are raised apart from ...
...n can be embarrassing, but a new study suggests th...from Turku, Finland, interviewed more than three t...der or younger brothers - about the first time the... that they had suffered from erectile dysfunction ...counter. These common problems are often attribute...
Other Biology News:Five outstanding young gastroenterologists receive AGA Foundation 2009 Research Scholars Award 2Five outstanding young gastroenterologists receive AGA Foundation 2009 Research Scholars Award 3A bad performance is better than no performance at all 2
Rubella IgM ELISA Kit, Single from Bio-Quant Inc.
EBV-VCA IgA ELISA Kit, Single from Bio-Quant Inc.
H. Pylori IgM ELISA Kit, Single from Bio-Quant Inc.
Mouse IgG2b EIA Kit from Assay Designs/Stressgen Bioreagents
Biology Products: